Infliximab for hidradenitis suppurativa: report of seven consecutive patients
Identifieur interne : 004109 ( Istex/Corpus ); précédent : 004108; suivant : 004110Infliximab for hidradenitis suppurativa: report of seven consecutive patients
Auteurs : Alain Dupuy ; Laurence Fardet ; Delphine Kerob ; Annabelle Levy ; Hervé Bachelez ; Patrice Morel ; Celeste LebbeSource :
- Experimental Dermatology [ 0906-6705 ] ; 2006-06.
Abstract
Purpose: To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS). Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow‐up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab. Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked (n = 1), moderate (n = 4) or null (n = 2). At week 10, five patients were evaluated and judged this efficacy as marked (n = 2), moderate (n = 2) or null (n = 1). The mean Skindex‐29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10. Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS.
Url:
DOI: 10.1111/j.0906-6705.2006.0436o.x
Links to Exploration step
ISTEX:8A06656ED8C310D1C1359881CEBB4BFF5981988CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Infliximab for hidradenitis suppurativa: report of seven consecutive patients</title><author><name sortKey="Dupuy, Alain" sort="Dupuy, Alain" uniqKey="Dupuy A" first="Alain" last="Dupuy">Alain Dupuy</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Fardet, Laurence" sort="Fardet, Laurence" uniqKey="Fardet L" first="Laurence" last="Fardet">Laurence Fardet</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Kerob, Delphine" sort="Kerob, Delphine" uniqKey="Kerob D" first="Delphine" last="Kerob">Delphine Kerob</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Levy, Annabelle" sort="Levy, Annabelle" uniqKey="Levy A" first="Annabelle" last="Levy">Annabelle Levy</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Bachelez, Herve" sort="Bachelez, Herve" uniqKey="Bachelez H" first="Hervé" last="Bachelez">Hervé Bachelez</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Morel, Patrice" sort="Morel, Patrice" uniqKey="Morel P" first="Patrice" last="Morel">Patrice Morel</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbe">Celeste Lebbe</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8A06656ED8C310D1C1359881CEBB4BFF5981988C</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1111/j.0906-6705.2006.0436o.x</idno><idno type="url">https://api.istex.fr/document/8A06656ED8C310D1C1359881CEBB4BFF5981988C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">004109</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004109</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Infliximab for hidradenitis suppurativa: report of seven consecutive patients</title><author><name sortKey="Dupuy, Alain" sort="Dupuy, Alain" uniqKey="Dupuy A" first="Alain" last="Dupuy">Alain Dupuy</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Fardet, Laurence" sort="Fardet, Laurence" uniqKey="Fardet L" first="Laurence" last="Fardet">Laurence Fardet</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Kerob, Delphine" sort="Kerob, Delphine" uniqKey="Kerob D" first="Delphine" last="Kerob">Delphine Kerob</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Levy, Annabelle" sort="Levy, Annabelle" uniqKey="Levy A" first="Annabelle" last="Levy">Annabelle Levy</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Bachelez, Herve" sort="Bachelez, Herve" uniqKey="Bachelez H" first="Hervé" last="Bachelez">Hervé Bachelez</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Morel, Patrice" sort="Morel, Patrice" uniqKey="Morel P" first="Patrice" last="Morel">Patrice Morel</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbe">Celeste Lebbe</name><affiliation><mods:affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Experimental Dermatology</title><title level="j" type="alt">EXPERIMENTAL DERMATOLOGY</title><idno type="ISSN">0906-6705</idno><idno type="eISSN">1600-0625</idno><imprint><biblScope unit="vol">15</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="482">482</biblScope><biblScope unit="page" to="482">482</biblScope><biblScope unit="page-count">1</biblScope><publisher>Blackwell Publishing Ltd/Inc.</publisher><pubPlace>Oxford, UK; Malden, USA</pubPlace><date type="published" when="2006-06">2006-06</date></imprint><idno type="ISSN">0906-6705</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0906-6705</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose: To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS). Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow‐up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab. Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked (n = 1), moderate (n = 4) or null (n = 2). At week 10, five patients were evaluated and judged this efficacy as marked (n = 2), moderate (n = 2) or null (n = 1). The mean Skindex‐29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10. Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>hidradenitis</json:string><json:string>suppurativa</json:string><json:string>hidradenitis suppurativa</json:string><json:string>follicle</json:string><json:string>dermatology</json:string><json:string>apocrine</json:string><json:string>acne</json:string><json:string>inversa</json:string><json:string>dessau</json:string><json:string>infliximab</json:string><json:string>epithelium</json:string><json:string>acne inversa</json:string><json:string>bulge cells</json:string><json:string>hair follicle</json:string><json:string>apocrine glands</json:string><json:string>follicular</json:string><json:string>sinus</json:string><json:string>terminal hair follicles</json:string><json:string>follicular hyperkeratosis</json:string><json:string>medical treatment</json:string><json:string>consecutive patients</json:string><json:string>primary closure</json:string><json:string>epidermis</json:string><json:string>hidradenitis suppurativa foundation</json:string><json:string>sweat glands</json:string><json:string>immune system</json:string><json:string>adsc transplantation</json:string><json:string>clinical pharmacology</json:string><json:string>blackwell munksgaard</json:string><json:string>epidermal basal cells</json:string><json:string>bulge cell progeny</json:string><json:string>mouse models</json:string><json:string>universitaetsmedizin berlin</json:string><json:string>squamous cell carcinoma</json:string><json:string>psychological impact</json:string><json:string>axillary apocrine secretory cells</json:string><json:string>domestic animals</json:string><json:string>clinical picture</json:string><json:string>keratinized epithelium</json:string><json:string>germany acne inversa</json:string><json:string>lesional epidermis</json:string><json:string>sinus tracts</json:string><json:string>outcome measures</json:string><json:string>campus benjamin franklin</json:string><json:string>germany hidradenitis suppurativa inversa</json:string><json:string>surgical treatment options</json:string><json:string>critical review</json:string><json:string>late phases</json:string><json:string>skin areas</json:string><json:string>range years</json:string><json:string>inflamed lesions</json:string><json:string>clinical trial</json:string><json:string>root sheath</json:string><json:string>active drug</json:string><json:string>adverse effects</json:string><json:string>such cells</json:string><json:string>hair follicles</json:string></teeft></keywords><author><json:item><name>Alain Dupuy</name><affiliations><json:string>Department of Dermatology, Hopital Saint‐Louis, Paris, France</json:string></affiliations></json:item><json:item><name>Laurence Fardet</name><affiliations><json:string>Department of Dermatology, Hopital Saint‐Louis, Paris, France</json:string></affiliations></json:item><json:item><name>Delphine Kerob</name><affiliations><json:string>Department of Dermatology, Hopital Saint‐Louis, Paris, France</json:string></affiliations></json:item><json:item><name>Annabelle Levy</name><affiliations><json:string>Department of Dermatology, Hopital Saint‐Louis, Paris, France</json:string></affiliations></json:item><json:item><name>Hervé Bachelez</name><affiliations><json:string>Department of Dermatology, Hopital Saint‐Louis, Paris, France</json:string></affiliations></json:item><json:item><name>Patrice Morel</name><affiliations><json:string>Department of Dermatology, Hopital Saint‐Louis, Paris, France</json:string></affiliations></json:item><json:item><name>Celeste Lebbe</name><affiliations><json:string>Department of Dermatology, Hopital Saint‐Louis, Paris, France</json:string></affiliations></json:item></author><articleId><json:string>EXD436O</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>abstract</json:string></originalGenre><abstract>Purpose: To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS). Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow‐up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab. Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked (n = 1), moderate (n = 4) or null (n = 2). At week 10, five patients were evaluated and judged this efficacy as marked (n = 2), moderate (n = 2) or null (n = 1). The mean Skindex‐29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10. Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS.</abstract><qualityIndicators><score>7.007</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractCharCount>1537</abstractCharCount><pdfWordCount>4175</pdfWordCount><pdfCharCount>28282</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>236</abstractWordCount></qualityIndicators><title>Infliximab for hidradenitis suppurativa: report of seven consecutive patients</title><genre><json:string>abstract</json:string></genre><host><title>Experimental Dermatology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1600-0625</json:string></doi><issn><json:string>0906-6705</json:string></issn><eissn><json:string>1600-0625</json:string></eissn><publisherId><json:string>EXD</json:string></publisherId><volume>15</volume><issue>6</issue><pages><first>482</first><last>482</last><total>1</total></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>science</json:string><json:string>dermatology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>dermatology & venereal diseases</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1111/j.0906-6705.2006.0436o.x</json:string></doi><id>8A06656ED8C310D1C1359881CEBB4BFF5981988C</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/8A06656ED8C310D1C1359881CEBB4BFF5981988C/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/8A06656ED8C310D1C1359881CEBB4BFF5981988C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/8A06656ED8C310D1C1359881CEBB4BFF5981988C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Infliximab for hidradenitis suppurativa: report of seven consecutive patients</title></titleStmt><publicationStmt><publisher>Blackwell Publishing Ltd/Inc.</publisher><pubPlace>Oxford, UK; Malden, USA</pubPlace><date type="published" when="2006-06"></date></publicationStmt><notesStmt><note type="content-type" subtype="abstract" source="abstract" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-HPN7T1Q2-R">abstract</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="abstract"><analytic><title level="a" type="main">Infliximab for hidradenitis suppurativa: report of seven consecutive patients</title><title level="a" type="short">HSF Abstracts</title><author xml:id="author-0000"><persName><forename type="first">Alain</forename><surname>Dupuy</surname></persName><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France<address><country key="FR"></country></address></affiliation><note type="foot">Presenting author.</note></author><author xml:id="author-0001"><persName><forename type="first">Laurence</forename><surname>Fardet</surname></persName><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Delphine</forename><surname>Kerob</surname></persName><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Annabelle</forename><surname>Levy</surname></persName><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Hervé</forename><surname>Bachelez</surname></persName><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Patrice</forename><surname>Morel</surname></persName><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Celeste</forename><surname>Lebbe</surname></persName><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France<address><country key="FR"></country></address></affiliation></author><idno type="istex">8A06656ED8C310D1C1359881CEBB4BFF5981988C</idno><idno type="DOI">10.1111/j.0906-6705.2006.0436o.x</idno><idno type="unit">EXD436O</idno><idno type="toTypesetVersion">file:EXD.EXD436o.pdf</idno></analytic><monogr><title level="j" type="main">Experimental Dermatology</title><title level="j" type="alt">EXPERIMENTAL DERMATOLOGY</title><idno type="pISSN">0906-6705</idno><idno type="eISSN">1600-0625</idno><idno type="book-DOI">10.1111/(ISSN)1600-0625</idno><idno type="book-part-DOI">10.1111/exd.2006.15.issue-6</idno><idno type="product">EXD</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">15</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="482">482</biblScope><biblScope unit="page" to="482">482</biblScope><biblScope unit="page-count">1</biblScope><publisher>Blackwell Publishing Ltd/Inc.</publisher><pubPlace>Oxford, UK; Malden, USA</pubPlace><date type="published" when="2006-06"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><p>
<hi rend="italic">Purpose:</hi> To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS).</p><p>
<hi rend="italic">Patients and methods:</hi> Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow‐up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab.</p><p>
<hi rend="italic">Results:</hi> Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked (<hi rend="italic">n</hi> = 1), moderate (<hi rend="italic">n</hi> = 4) or null (<hi rend="italic">n</hi> = 2). At week 10, five patients were evaluated and judged this efficacy as marked (<hi rend="italic">n</hi> = 2), moderate (<hi rend="italic">n</hi> = 2) or null (<hi rend="italic">n</hi> = 1). The mean Skindex‐29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10.</p><p>
<hi rend="italic">Conclusion:</hi> The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS.</p></abstract><textClass><classCode scheme="tocHeading1">ABSTRACTS</classCode></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/8A06656ED8C310D1C1359881CEBB4BFF5981988C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley component found"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd/Inc.</publisherName><publisherLoc>Oxford, UK; Malden, USA</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0625</doi><issn type="print">0906-6705</issn><issn type="electronic">1600-0625</issn><idGroup><id type="product" value="EXD"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="EXPERIMENTAL DERMATOLOGY">Experimental Dermatology</title></titleGroup></publicationMeta><publicationMeta level="part" position="06006"><doi origin="wiley">10.1111/exd.2006.15.issue-6</doi><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue" number="6">6</numbering></numberingGroup><coverDate startDate="2006-06">June 2006</coverDate></publicationMeta><publicationMeta level="unit" type="abstract" position="0048200" status="forIssue"><doi origin="wiley">10.1111/j.0906-6705.2006.0436o.x</doi><idGroup><id type="unit" value="EXD436O"></id></idGroup><countGroup><count type="pageTotal" number="1"></count></countGroup><titleGroup><title type="tocHeading1">ABSTRACTS</title></titleGroup><eventGroup><event type="firstOnline" date="2008-06-28"></event><event type="publishedOnlineFinalForm" date="2008-06-28"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.15 mode:FullText source:Header result:Header" date="2010-07-19"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-25"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-17"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="482">482</numbering><numbering type="pageLast" number="482">482</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:EXD.EXD436o.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="0"></count><count type="wordTotal" number="4488"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Infliximab for hidradenitis suppurativa: report of seven consecutive patients</title><title type="shortAuthors">HSF Abstracts</title><title type="short">HSF Abstracts</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" noteRef="#fn1"><personName><givenNames>Alain</givenNames><familyName>Dupuy</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>Laurence</givenNames><familyName>Fardet</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>Delphine</givenNames><familyName>Kerob</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1"><personName><givenNames>Annabelle</givenNames><familyName>Levy</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a1"><personName><givenNames>Hervé</givenNames><familyName>Bachelez</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a1"><personName><givenNames>Patrice</givenNames><familyName>Morel</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a1"><personName><givenNames>Celeste</givenNames><familyName>Lebbe</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="FR"><unparsedAffiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><p> <i>Purpose:</i> To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS).</p><p> <i>Patients and methods:</i> Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow‐up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab.</p><p> <i>Results:</i> Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked (<i>n</i> = 1), moderate (<i>n</i> = 4) or null (<i>n</i> = 2). At week 10, five patients were evaluated and judged this efficacy as marked (<i>n</i> = 2), moderate (<i>n</i> = 2) or null (<i>n</i> = 1). The mean Skindex‐29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10.</p><p> <i>Conclusion:</i> The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><label>*</label><p>Presenting author.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Infliximab for hidradenitis suppurativa: report of seven consecutive patients</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>HSF Abstracts</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Infliximab for hidradenitis suppurativa: report of seven consecutive patients</title></titleInfo><name type="personal"><namePart type="given">Alain</namePart><namePart type="family">Dupuy</namePart><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</affiliation><description>Presenting author.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laurence</namePart><namePart type="family">Fardet</namePart><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Delphine</namePart><namePart type="family">Kerob</namePart><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Annabelle</namePart><namePart type="family">Levy</namePart><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hervé</namePart><namePart type="family">Bachelez</namePart><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Patrice</namePart><namePart type="family">Morel</namePart><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Celeste</namePart><namePart type="family">Lebbe</namePart><affiliation>Department of Dermatology, Hopital Saint‐Louis, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="abstract" displayLabel="abstract"></genre><originInfo><publisher>Blackwell Publishing Ltd/Inc.</publisher><place><placeTerm type="text">Oxford, UK; Malden, USA</placeTerm></place><dateIssued encoding="w3cdtf">2006-06</dateIssued><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="words">4488</extent></physicalDescription><abstract lang="en">Purpose: To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS). Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow‐up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab. Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked (n = 1), moderate (n = 4) or null (n = 2). At week 10, five patients were evaluated and judged this efficacy as marked (n = 2), moderate (n = 2) or null (n = 1). The mean Skindex‐29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10. Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS.</abstract><relatedItem type="host"><titleInfo><title>Experimental Dermatology</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0906-6705</identifier><identifier type="eISSN">1600-0625</identifier><identifier type="DOI">10.1111/(ISSN)1600-0625</identifier><identifier type="PublisherID">EXD</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>482</start><end>482</end><total>1</total></extent></part></relatedItem><identifier type="istex">8A06656ED8C310D1C1359881CEBB4BFF5981988C</identifier><identifier type="DOI">10.1111/j.0906-6705.2006.0436o.x</identifier><identifier type="ArticleID">EXD436O</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd/Inc.</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004109 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 004109 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8A06656ED8C310D1C1359881CEBB4BFF5981988C
|texte= Infliximab for hidradenitis suppurativa: report of seven consecutive patients
}}
| This area was generated with Dilib version V0.6.31. |  |